Current guidelines recommend the combination of endocrine treatment (aromatase inhibitor or fulvestrant) and a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) as first-line treatment for advanced HR+/HER2− breast cancer [6]. This evidence concerns the gene CDK4 and breast carcinoma.